ClinicalTrials.gg
RecruitingNCT07292610NUTS4BRAIN-RCTUpdated Dec 18, 2025

Impact of Nut Consumption on Mental Health in Young Adults

An interventional study of mixed nuts. Group A and mixed nuts. Group B in Depression Disorder, Anxiety and Mental Health, sponsored by University of Castilla-La Mancha. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-18.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Castilla-La Mancha · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 225 studies in Depression with a site in Spain — 46 open to participants now, 58 under way, 7 of them phase 3. Depression · Spain.

Planned enrollment
89th of 189
135 · median 123
Started
2025
with 20 others
No phase
153 of 225
35 open now
Primary completion
2026-12
later than 33 of 57 live
Registered
203rd of 225
by date

Among the 225 studies in Depression with a site in Spain, this one is the 89th largest by planned enrollment of the 189 interventional ones that give a count, is one of 21 that started in 2025, is one of 153 with no phase, reaches primary completion later than 33 of the 57 other live ones, and was the 203rd registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

46 of the 225 studies in Depression with a site in Spain are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 24 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 225 studies in Depression with a site in Spain, or all of them as a file.
02

Study summary

Nuts have a high nutrient density, and numerous studies have reported their cardiometabolic benefits. Although observational studies in adults have indicated a potential link between nut consumption and improved mental health, there is still insufficient evidence from experimental studies to draw firm conclusions about this association.

Read the detailed description

Nuts are widely recognized for their high nutrient density and their multiple reported cardiometabolic benefits. They are rich in monounsaturated (MUFAs) and polyunsaturated (PUFAs) fatty acids (including omega-3 alpha-linolenic acid and omega-6 linoleic acid) as well as antioxidants and compounds with anti inflammatory properties. Observational studies in adults have suggested a potential association between nut consumption and improved mental health, including a reduced risk of depression and enhanced mood. However, evidence from experimental studies remains limited and often inconclusive.

Early adulthood (ages 18-24) represents a critical developmental period marked by substantial physical, psychological, and social changes, and it is also a stage during which mental health problems commonly emerge.

The Nuts4Brain-RCT will investigate the impact of a 6-month mixed-nut intervention on mental health symptoms, cognitive functioning, sleep quality, overall well-being, health-related quality of life, and biochemical mediators of brain function and mental health in young adults.

03

Conditions studied

  • Depression Disorder
  • Anxiety
  • Mental Health
  • Stress
  • Cognition
  • BDNF
  • General Wellbeing

Keywords

  • RCT
  • Dietary Intervention
  • Nut consumption
  • young adults
  • Randomized controlled trial
  • Mental Health
  • Depression
  • Anxiety
  • Cognition
  • University students
  • Sleep quality
  • Academic performance
  • Walnuts
  • Almonds
  • Pistachios
  • Hazelnut
  • BDNF
04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 135 is above the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

University of Castilla-La Mancha is the lead sponsor of 108 studies on the registry; 26 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Participants must meet all the following criteria to be considered eligible for selection and randomization:

Inclusion criteria

Inclusion Criteria:

  • Age: Participants must be between 18 and 25 years old.
  • Academic Status: Participants must be enrolled as university students.
  • Field of Study: Participants may come from any academic program offered at the Cuenca Campus, including Nursing, Social Work, Education, Fine Arts, Engineering, Journalism, and Teaching.

Participants will be excluded from the study if they have any of the following conditions, based on self-reported information:

Exclusion criteria

Exclusion Criteria:

  • Allergies: Known nut allergy.
  • Self-reported cardiovascular, metabolic, gastrointestinal or mental health disorder.
06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Active comparator
    Control Group

    Usual dietary habits.

    Other: control group

  • Experimental
    Intervention Group A

    Nut consumption (walnuts, almonds, pistachios, and hazelnuts mix).

    Dietary Supplement: mixed nuts. Group A

  • Experimental
    Intervention Group B

    Nut consumption (walnuts, almonds, pistachios, and hazelnuts mix).

    Dietary Supplement: mixed nuts. Group B

Interventions

  • Dietary supplementmixed nuts. Group A

    Participants will be instructed to consume a single daily dose of nuts (30 g/day of mixed nuts). Nuts will be provided free of charge for the entire study period (6 moths). The participants will be instructed to incorporate nuts into their regular diet and consume them in any way they prefer. Upon completion of the intervention, participants will be instructed to continue their usual dietary and lifestyle habits, without any specific restrictions or incentives directed toward nut consumption. After 6 months have passed since the end of the intervention, all participants will be called for a final session (12 months) in which all data evaluated throughout the study will be collected

  • Dietary supplementmixed nuts. Group B

    Participants will be instructed to consume two daily doses of nuts (60 g/day of mixed nuts). Nuts will be provided free of charge for the entire study period (6 months). The participants will be instructed to incorporate nuts into their regular diet and consume them in any way they prefer.Upon completion of the intervention, participants will be instructed to continue their usual dietary and lifestyle habits, without any specific restrictions or incentives directed toward nut consumption. After 6 months have passed since the end of the intervention, all participants will be called for a final session (12 months) in which all data evaluated throughout the study will be collected

  • Othercontrol group

    Participants will be instructed to maintain their regular diet without any specific dietary instructions or intervention.

07

What researchers measure

Primary outcomes

  1. Depression

    Changes in symptoms of depression assessed with the Beck Depression Inventory Version II (BDI-II). Each of the 21 items includes four statements of increasing severity, and a total score (ranging from 0 to 63) is calculated, with higher scores indicating more severe depression.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  2. Anxiety

    Changes in symptoms of anxiety assessed with The Generalized Anxiety Disorder 7-item (GAD-7). The GAD-7 consists of seven questions asking individuals to rate the frequency and severity of specific anxiety symptoms over the past two weeks.The total score ranges from 0 to 21, calculated by summing the scores of all seven items. A score of 10 or greater is considered a reasonable cut-off point for identifying possible cases of GAD that may require further clinical evaluation

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  3. Stress

    Changes in symptoms of stress assessed with The Perceived Stress Scale (PSS-10). The PSS-10 is a widely used, 10-item self-report questionnaire that measures an individual's perception of stress over the past month. Scoring involves reverse-scoring four positive items and summing all 10. Total scores range from 0 to 40, with higher scores indicating more perceived stress. Scores can be interpreted generally as low (0-13), moderate (14-26), or high (27-40) stress.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  4. Episodic memory

    The Picture Sequence Memory Test assesses episodic memory by requiring participants to encode and recall the temporal order of a sequence of visually presented everyday events. After presentation, individuals are asked to reconstruct the sequence in its original order, allowing evaluation of visual episodic memory and learning across trials. Test time: 7 minutes. This test is one of the measures included in the NIH Toolbox Cognition Battery, which is administered on an iPad by qualified personnel.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  5. Working memory

    The List Sorting Working Memory Test (LSWM), part of the NIH Toolbox Cognition Batery, assesses working memory by having individuals recall and sequence visually and auditorily presented stimuli (like animal/food pictures) in size order (smallest to largest). Test time: 7 minutes.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  6. Cognitive flexibility

    The Dimensional Change Card Sort Test is a standardized measure of cognitive flexibility. Participants are required to sort cards according to different rules (e.g., color or shape) and to adapt their responses when the sorting dimension changes. Test time: 5 minutes. This test is one of the tests that will be determined using the NIH Toolbox Cognition Battery, which will be administered on an iPad by qualified personnel.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  7. Processing speed

    The Pattern Comparison Processing Speed Test is a standardized measure of processing speed. Participants are asked to quickly determine whether two visual patterns are the same or different, emphasizing speed and accuracy of visual perception and decision-making. Test Time: 4 minutes. This test is one of the tests that will be determined using the NIH Toolbox Cognition Battery, which will be administered on an iPad by qualified personnel.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  8. Inhibitory control and attention

    The Flanker Inhibitory Control and Attention Test is a standardized measure of inhibitory control and selective attention, core components of executive function. Participants are required to focus on a central target stimulus while inhibiting interference from surrounding distractor stimuli. Performance reflects the ability to maintain attention, suppress competing responses, and resolve cognitive conflict. Test Time: 3 minutes. This test is one of the tests that will be determined using the NIH Toolbox Cognition Battery, which will be administered on an iPad by qualified personnel.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  9. Brain Derived Neurotrophic Factor

    Changes in blood concentration of brain-derived neurotrophic factor (BDNF), a biochemical mediator of brain functioning

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

Secondary outcomes

  1. Sleep quality

    Changes in quality of sleep assessed with the Pittsburgh Sleep Quality Index (PSQI). The PSQI consists of 19 individual self-rated questions (and 5 optional questions for a roommate/bed partner) that are grouped into seven component scores. Each of the seven components is scored on a scale of 0 to 3, where 0 indicates no difficulty and 3 indicates severe difficulty. The scores of these components are summed to produce a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  2. Health-related quality of life (HRQL)

    Changes in health-related quality of life assessed with the SF12 questionnaire. It consists of 12 questions that cover the same eight health domains as the longer SF-36: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health. The 12 items are used to create two main summary measures through a complex, norm-based scoring algorithm: Physical Component Summary (PCS): A single score representing physical health status. Mental Component Summary (MCS): A single score representing mental and emotional health status. Interpretation of Scores: Scores for both PCS and MCS typically range from 0 to 100, where higher scores indicate better health and functioning.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  3. Inflammatory biomarkers

    Changes in blood inflammatory markers (e.g. hs-CRP) to examine underlying mechanisms

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  4. Concentration of vitamins and minerals

    Changes in blood concentration of specific vitamins and minerals (e.g., vitamins B9, B12, D, iron, and magnesium) to examine underlying mechanisms

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  5. Body image

    Changes in body image perception using The Standard Figural Stimuli (SFS). Measurement Purpose: Perceived Body Image: The figure the individual selects as most representative of their current body size. Ideal Body Image: The figure the individual would like to have. Body Dissatisfaction: The discrepancy between the perceived image and the ideal image. A larger difference indicates greater body dissatisfaction.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  6. Screen time

    Screen time will be assessed using an ad hoc questionnaire that records the number of hours of leisure time participants spend watching television, using a mobile phone, using a computer for work-related purposes, or engaging with other electronic devices, both on weekdays and during weekends.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  7. Social media addiction

    Changes in social media addiction through Social Network Addiction Questionnaire, 6-item version (ARS-6). The scale typically consists of 6 items, with one item representing each of the six components of addiction. Response Scale: Responses are typically given on a 5-point Likert scale (e.g., from 1 = Not at all to 5 = Always). Scoring: Item responses are summed to obtain a total score, ranging from 6 to 30. Higher scores indicate a greater risk or severity of social media addiction.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  8. Sociodemographic

    Sociodemographic information such as age, sex, date of birth, country of origin, marital status, housing type, medication use, and family history of mental or cardiovascular disorders.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  9. Drugs consumption

    Changes in drugs consumption assessed with the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). The ASSIST generates substance-specific risk scores that categorize use into low, moderate, or high-risk categories. Higher scores indicate a greater risk of substance-related health and social problems, guiding the type of intervention needed (e.g., brief intervention or referral to specialist treatment).

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  10. Adherence to the Mediterranean Diet

    Changes in adherence to the mediterranean diet assessed with the MEDAS questionnaire. Scoring: Each item is scored with 1 point if the criteria for adherence to the Mediterranean diet are met, and 0 points if they are not. The total score ranges from 0 to 14 points. Higher scores indicate greater adherence to the Mediterranean diet. A common cut-off point of ≥9 is often used to define good adherence to the diet.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  11. Resilience

    Changes in resilience assessed with the Connor-Davidson Resilience Scale (CD-RISC 10). Each item is rated on a 5-point Likert scale ranging from 0 (not true at all) to 4 (true nearly all the time). The total score is calculated by summing the values of all 10 items. Total scores range from 0 to 40. Higher scores on the CD-RISC 10 indicate greater resilience and a better ability to cope with adversity and bounce back from difficult experiences.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  12. Risk of eating disorders

    The SCOFF questionnaire (an acronym derived from the initials of its English questions: Sick, Control, One stone, Fat, Food) is a brief and simple, five-question screening tool designed to detect the possible presence of eating disorders (EDs), such as anorexia nervosa and bulimia nervosa. The total score can range from 0 to 5. A score of two or more points is considered a positive screening result and suggests a suspicion of an ED that requires a detailed formal clinical assessment.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  13. Weight

    Weight in kilograms will be assessed twice using a calibrated digital scale (Scale Seca® 861) with participants barefoot and in light weight clothing.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  14. Height

    Height will be measured twice with a stadiometer (Wall stadiometer Seca® 222), with participants standing upright, barefoot, and with the sagittal midline aligned to the wall.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  15. Body Mass Index (BMI)

    BMI will be calculated as weight divided by height squared (kg/m2).

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  16. Body fat percentage

    Body fat percentage will be assessed twice using the bioimpedance analysis system under standardized conditions (morning, fasting, post-void, after 15 minutes rest, barefoot, with controlled temperature and humidity).

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  17. Blood pressure

    Blood pressure will be measured using an automated device (OMRON® M5-I (Omron Healthcare UK Ltd.)). Systolic and diastolic blood pressure will be assessed twice, with a 5-minute interval between measurements. Participants will be seated in a quiet environment, with the right arm semi-flexed at heart level.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  18. Muscular strenght

    Measured through handgrip strength using a calibrated dynamometer (Digital dynamometer TKK 5401 Grip-D (Takey®, Tokyo, Japan), and standing long jump for lower body strength. Handgrip: Kilograms (kg). Horizontal jump: Centimeters (cm).

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  19. Phisical activity

    Changes in phisical activity assessed with the The International Physical Activity Questionnaire (IPAQ). The data collected with the IPAQ can be reported as a continuous measure (estimation of total energy expenditure in MET-minutes per week) or categorically (classifying individuals into low, moderate, or high physical activity levels): Continuous Score: Total energy expenditure is calculated using specific formulas that assign MET (metabolic equivalent) values to each activity type (walking=3.3 METs, moderate=4.0 METs, vigorous=8.0 METs). Categorical Score: Participants are classified into three levels of physical activity based on predefined criteria related to the duration, frequency, and intensity of activities.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  20. Lipid profile

    Changes in blood lipid profile (Cholesterol (Total, HDL-c, LDL-c), triglycerides)) to examine underlying mechanisms.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  21. Glucose levels

    Changes in blood glucose levels to examine underlying mechanisms.

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

  22. Hemoglobin A1c (HbA1c)

    Changes in blood HbA1c levels to examine underlying mechanisms.

    Time frame: Day 0", "Month 3", "Month 6", "Month 12"

  23. Adherence verification

    Adherence to nut consumption intervention measured by blood levels of vitamin E

    Time frame: "Day 0", "Month 3", "Month 6", "Month 12"

08

Study locations

1 of 1 sites recruiting
  • Health and Social Research Center. University of Castilla-La Mancha
    Cuenca, Cuenca 16071, Spain
    Recruiting
09

References and documents

Publications

  • Mesas AE, Peral-Martinez F, Olivo-Martins-de-Passos T, Jimenez-Lopez E, Beneit N, Martinez-Ortega IA, Diaz-Goni V, Herraiz-Garrote S, Martinez-Garcia I, Casanova-Rodriguez D, Rodriguez-Gutierrez E, Bizzozero-Peroni B, Ballesta-Castillejos A, Cekrezi S, Marcilla-Toribio I, Nunez de Arenas-Arroyo S, Alvarez-Herraiz C, Maia CSC, Machado SP, Oliveira LFN, Serrano-Martinez S, Martinez-Madrid V, Calderon-Alva MC, Lopez-Gil JF, Fernandez-Rodriguez R, Cadenas-Sanchez C, Medrano M, Visier-Alfonso ME, Martinez-Vizcaino V, Garrido-Miguel M. Nuts4Brain-RCT: Protocol for a Three-Arm Randomized Controlled Trial Examining the Dose-Response Effects of Nut Consumption on Mental Health in Young Adults. Healthcare (Basel). 2026 Feb 9;14(4):435. doi: 10.3390/healthcare14040435. PubMed 41753948 ↗

Individual participant data

Plan to share: Yes — The data generated in this project will be publicly shared through Zenodo an open-access repository compliant with FAIR (Findable, Accessible, Interoperable, and Reusable) principles.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: These data will remain accessible for a minimum period of five years.

Access criteria: All data will be securely stored under the responsibility of the project's Principal Investigator, Arthur Eumann Mesas, ensuring compliance with institutional and ethical data protection requirements.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 13 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Dec 18, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Apr 2027
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07292610
Collaborators
European Union
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Nov 24, 2025
Primary completion
Dec 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Dec 18, 2025

Study contacts

Arthur Eumann Mesas, PdD
Contact
arthur.emesas@uclm.es
+34 926053716
Miriam Garrido-Miguel, PhD
Contact
miriam.garrido@uclm.es
+34 926054003
Arthur Eumann Mesas, PhD
principal investigator · Health and Social Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion